Brii Biosciences Ltd. Partners with Joincare Group to Advance BRII-693 for Antimicrobial Resistance in Greater China

Reuters

Jul 04

Brii Biosciences Ltd. Partners with Joincare Group to Advance BRII-693 for Antimicrobial Resistance in Greater China

Brii Biosciences Ltd. has announced a new licensing agreement with Joincare Group for the development and commercialization of BRII-693, a novel hospital antibiotic, in the Greater China region. Under this agreement, Joincare Group will take charge of clinical development, regulatory approval, and commercialization. The collaboration is aimed at addressing the growing threat of antimicrobial resistance, with early data indicating BRII-693's potential as a best-in-class therapy. Brii Biosciences will retain rights outside Greater China and will continue investing in other projects. The results of the clinical trials for BRII-693 have not yet been presented and will be shared in future communications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN24169) on July 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2548336219"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548336219\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548336219?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-04 08:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548336219","market":"us","top_or_hot":-1,"title":"Brii Biosciences Ltd. Partners with Joincare Group to Advance BRII-693 for Antimicrobial Resistance in Greater China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Brii Biosciences Ltd. Partners with Joincare Group to Advance BRII-693 for Antimicrobial Resistance in Greater China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Brii Biosciences Ltd. has announced a new licensing agreement with Joincare Group for the development and commercialization of BRII-693, a novel hospital antibiotic, in the Greater China region. Under this agreement, Joincare Group will take charge of clinical development, regulatory approval, and commercialization. The collaboration is aimed at addressing the growing threat of antimicrobial resistance, with early data indicating BRII-693's potential as a best-in-class therapy. Brii Biosciences will retain rights outside Greater China and will continue investing in other projects. The results of the clinical trials for BRII-693 have not yet been presented and will be shared in future communications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN24169) on July 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Brii Biosciences Ltd. Partners with Joincare Group to Advance BRII-693 for Antimicrobial Resistance in Greater China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrii Biosciences Ltd. Partners with Joincare Group to Advance BRII-693 for Antimicrobial Resistance in Greater China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-04 08:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Brii Biosciences Ltd. Partners with Joincare Group to Advance BRII-693 for Antimicrobial Resistance in Greater China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Brii Biosciences Ltd. has announced a new licensing agreement with Joincare Group for the development and commercialization of BRII-693, a novel hospital antibiotic, in the Greater China region. Under this agreement, Joincare Group will take charge of clinical development, regulatory approval, and commercialization. The collaboration is aimed at addressing the growing threat of antimicrobial resistance, with early data indicating BRII-693's potential as a best-in-class therapy. Brii Biosciences will retain rights outside Greater China and will continue investing in other projects. The results of the clinical trials for BRII-693 have not yet been presented and will be shared in future communications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN24169) on July 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0077","symbol_name":"质押式回购","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250704:nNDL7yT8W1:1","article_id":"2548336219","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548336219","pubTimestamp":1751589021,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Brii Biosciences Ltd. has announced a new licensing agreement with Joincare Group for the development and commercialization of BRII-693, a novel hospital antibiotic, in the Greater China region. Under this agreement, Joincare Group will take charge of clinical development, regulatory approval, and commercialization. The collaboration is aimed at addressing the growing threat of antimicrobial resistance, with early data indicating BRII-693's potential as a best-in-class therapy. Brii Biosciences will retain rights outside Greater China and will continue investing in other projects. The results of the clinical trials for BRII-693 have not yet been presented and will be shared in future communications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or leg","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600380":"健康元","BK0077":"质押式回购","BK0046":"生物疫苗","BK0028":"国家队","BK0239":"医药制造","02137":"腾盛博药-B","BK1161":"生物科技","BK0114":"健康中国","BK1587":"次新股","BK1574":"生物医药B类股","BK0188":"融资融券"},"translate_title":"Brii Biosciences Ltd.与健康元集团合作，在大中华区推进BRII-693治疗抗生素耐药性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600380":0.9,"02137":0.9},"content_text":"Brii Biosciences Ltd. Partners with Joincare Group to Advance BRII-693 for Antimicrobial Resistance in Greater China\n    \n\n        Brii Biosciences Ltd. has announced a new licensing agreement with Joincare Group for the development and commercialization of BRII-693, a novel hospital antibiotic, in the Greater China region. Under this agreement, Joincare Group will take charge of clinical development, regulatory approval, and commercialization. The collaboration is aimed at addressing the growing threat of antimicrobial resistance, with early data indicating BRII-693's potential as a best-in-class therapy. Brii Biosciences will retain rights outside Greater China and will continue investing in other projects. The results of the clinical trials for BRII-693 have not yet been presented and will be shared in future communications.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN24169) on July 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}